Medigen, Inc. is a preclinical biomedical company that specializes in the development of safe and effective vaccines for emerging infectious diseases and cancer.
We develop our vaccines by using novel vaccine technologies such as virus-like particles (VLPs) and genetic vectors. Medigen also develops new ways of vaccine delivery for effective and safe immunization.
Our experimental vaccines include vaccines against pandemic influenza, chikungunya fever, Lassa fever, and other emerging, re-emerging, and biodefense-relevant infectious diseases. Medigen also develops prostate cancer vaccine.
In addition to vaccine development, we perform contract research and assist our customers in their research and development needs.
Medigen, Inc. conducts scientific research and vaccine development in the areas of infectious diseases and cancer. Medigen scientists are the leading experts in these areas.
We developed unique platform technologies for vaccination against infectious diseases and cancer. These platform technologies are applicable to the vaccine development against many diseases that affect millions of people in the U.S. and worldwide.
Using our platform technologies, we developed candidate vaccines for pandemic influenza, chikungunya fever, Lassa fever, VEE virus, yellow fever, and prostate cancer.
For partnership opportunities, please contact email@example.com
We provide our customers with expert contract research services, including experiment design, intellectual property development, and publishing and presenting data to the scientific community and government agencies. Our expertise includes production of viruses and virus-like particles, characterization of VLPs and purification of VLPs. Contact us for further details or request a quote at
In recent months, we had several important developments. To name just a few:
02/11/2015 Medigen presents new results on yellow fever vaccine at the ASM Biodefense conference in Washington, D.C.
09/14/2014 Article "Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice" is published in Vaccine by Medigen in collaboration with the University of Louisville (UofL), KY.
08/02/2014 Medigen and the University of Louisville collaborate on the development of replicon-based VLPV vaccine for Lassa fever.
07/28/2014 Medigen in collaboration with UTMB and UofL presents positive preclinical results with proprietary iDNA vaccines for alphaviruses including VEE and Chikungunya at the International Congress of Virology, Montreal, Canada.
06/21/2014 Medigen in collaboration with UTMB and UofL presents positive preclinical results on novel iDNA vaccines for VEE and Chikungunya viruses at the American Society for Virology meeting, Fort Collins, CO.
06/15/2014 Article "DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice" is published in the Journal of Infectious Diseases by Medigen in collaboration with the University of Texas Medical Branch (UTMB), Galveston, TX.
06/04/2014 Medigen reports positive results of influenza research at the VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES (VLPNPV) meeting in LaJolla, CA.
04/08/2014 Medigen receives U.S. Patent 8,691,563"IDNA vaccines and methods for using the same"
04/07/2014 Medigen and the University of Maryland, Baltimore (UMB) present positive preclinical results on replicon-based VLPV vaccine against prostate cancer at the American Association for Cancer Research meeting, San Diego, CA.
Copyright 2017 Medigen, Inc. All rights reserved.